You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameColistin
Accession NumberDB00803  (APRD00886)
TypeSmall Molecule
GroupsApproved
Description

Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally. [PubChem]

Structure
Thumb
Synonyms
SynonymLanguageCode
ColistinGermanINN
ColistinaSpanishINN
ColistineFrenchINN
ColistinumLatinINN
Polymyxin ENot AvailableIS
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Colistimethateinjection150 mg/2mLintramuscular; intravenousJHP Pharmaceuticals, LLC2012-06-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Colistimethateinjection, powder, lyophilized, for solution150 mg/2mLintramuscular; intravenousSagent Pharmaceuticals2014-12-29Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Colistimethateinjection, powder, lyophilized, for solution150 mgintramuscular; intravenousX Gen Pharmaceuticals, Inc.2011-01-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Colistimethateinjection, powder, lyophilized, for solution150 mg/2mLintramuscular; intravenousFresenius Kabi USA, LLC2009-12-04Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Over the Counter ProductsNot Available
International Brands
NameCompany
AlfacolinCatalysis
AlficetinNova Argentia
ColiFinPari Pharma
ColimicinaQuimifar
ColimycineSanofi Aventis
ColiracinRafa
ColistateAtlantic Lab
ColomycinForest
Coly-MycinKing Pharmaceuticals
Diarönt monoCNP
PromixinProfile Pharma
TadimAllertec
WalamycinWallace
Brand mixtures
Brand NameIngredients
Colimy CColistin and Chloramphenicol
Colimy FoamColistin and Neomycin
Colimycin TColistin and Tetracycline
SulopredColistin and Erythromycin
Salts
Name/CASStructureProperties
Colistin Sodium Methansulfonate
ThumbNot applicableDBSALT000944
Colistin sulfate
ThumbNot applicableDBSALT000691
Categories
CAS number1264-72-8
WeightAverage: 1155.4339
Monoisotopic: 1154.749927302
Chemical FormulaC52H98N16O13
InChI KeyYKQOSKADJPQZHB-QNPLFGSASA-N
InChI
InChI=1S/C52H98N16O13/c1-9-29(6)11-10-12-40(71)59-32(13-19-53)47(76)68-42(31(8)70)52(81)64-35(16-22-56)44(73)63-37-18-24-58-51(80)41(30(7)69)67-48(77)36(17-23-57)61-43(72)33(14-20-54)62-49(78)38(25-27(2)3)66-50(79)39(26-28(4)5)65-45(74)34(15-21-55)60-46(37)75/h27-39,41-42,69-70H,9-26,53-57H2,1-8H3,(H,58,80)(H,59,71)(H,60,75)(H,61,72)(H,62,78)(H,63,73)(H,64,81)(H,65,74)(H,66,79)(H,67,77)(H,68,76)/t29?,30-,31-,32+,33+,34+,35+,36+,37+,38+,39-,41+,42+/m1/s1
IUPAC Name
N-[(1S)-3-amino-1-{[(1S,2R)-1-{[(1S)-3-amino-1-{[(3S,6S,9S,12S,15R,18S,21S)-6,9,18-tris(2-aminoethyl)-3-[(1R)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptaazacyclotricosan-21-yl]carbamoyl}propyl]carbamoyl}-2-hydroxypropyl]carbamoyl}propyl]-5-methylheptanamide
SMILES
[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCC(C)CC)[C@@H](C)O)[C@@H](C)O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as polypeptides. These are peptides containing ten or more amino acid residues.
KingdomOrganic compounds
Super ClassOrganic Polymers
ClassPolypeptides
Sub ClassNot Available
Direct ParentPolypeptides
Alternative Parents
Substituents
  • Polypeptide
  • Cyclic alpha peptide
  • N-acyl-alpha amino acid or derivatives
  • Macrolactam
  • Alpha-amino acid amide
  • N-substituted-alpha-amino acid
  • Fatty acyl
  • N-acyl-amine
  • Fatty amide
  • Secondary carboxylic acid amide
  • Secondary alcohol
  • Lactam
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Primary aliphatic amine
  • Carbonyl group
  • Amine
  • Alcohol
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli, particularly Pseudomonas aeruginosa.
PharmacodynamicsColistin is a polymyxin antibiotic agent. Polymyxins are cationic polypeptides that disrupt the bacterial cell membrane through a detergentlike mechanism. With the development of less toxic agents, such as extended-spectrum penicillins and cephalosporins, parenteral polymyxin use was largely abandoned, except for the treatment of multidrug-resistant pulmonary infections in patients with cystic fibrosis. More recently, however, the emergence of multidrug-resistant gram-negative bacteria, such as Pseudomonas aeruginosa and Acinetobacter baumannii, and the lack of new antimicrobial agents have led to the revived use of the polymyxins.
Mechanism of actionColistin is a surface active agent which penetrates into and disrupts the bacterial cell membrane. Colistin is polycationic and has both hydrophobic and lipophilic moieties. It interacts with the bacterial cytoplasmic membrane, changing its permeability. This effect is bactericidal. There is also evidence that polymyxins enter the cell and precipitate cytoplasmic components, primarily ribosomes.
AbsorptionVery poor absorption from gastrointestinal tract.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

As 80% of the dose can be recovered unchanged in the urine, and there is no biliary excretion, it can be assumed that the remaining drug is inactivated in the tissues, however the mechanism is unknown.

Route of eliminationNot Available
Half life5 hours
ClearanceNot Available
ToxicityOral LD50 in rats is 5450 mg/kg. Overdosage with colistimethate can cause neuromuscular blockade characterized by paresthesia, lethargy, confusion, dizziness, ataxia, nystagmus, disorders of speech and apnea. Respiratory muscle paralysis may lead to apnea, respiratory arrest and death.
Affected organisms
  • Gram-negative bacilli
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.7444
Blood Brain Barrier-0.9752
Caco-2 permeable-0.7492
P-glycoprotein substrateSubstrate0.8048
P-glycoprotein inhibitor INon-inhibitor0.7514
P-glycoprotein inhibitor IINon-inhibitor0.8582
Renal organic cation transporterNon-inhibitor0.9525
CYP450 2C9 substrateNon-substrate0.893
CYP450 2D6 substrateNon-substrate0.7907
CYP450 3A4 substrateNon-substrate0.513
CYP450 1A2 substrateNon-inhibitor0.9372
CYP450 2C9 substrateNon-inhibitor0.9387
CYP450 2D6 substrateNon-inhibitor0.929
CYP450 2C19 substrateNon-inhibitor0.9139
CYP450 3A4 substrateNon-inhibitor0.8879
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9937
Ames testNon AMES toxic0.8807
CarcinogenicityNon-carcinogens0.8947
BiodegradationNot ready biodegradable0.9515
Rat acute toxicity3.0728 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9855
hERG inhibition (predictor II)Non-inhibitor0.8646
Pharmacoeconomics
Manufacturers
  • Parke davis div warner lambert co
Packagers
Dosage forms
FormRouteStrength
Injectionintramuscular; intravenous150 mg/2mL
Injection, powder, lyophilized, for solutionintramuscular; intravenous150 mg
Injection, powder, lyophilized, for solutionintramuscular; intravenous150 mg/2mL
Prices
Unit descriptionCostUnit
Colistin sulfate powder513.26USD each
Coly-Mycin S 3.3-3-10 mg/ml Suspension 5ml Bottle49.17USD bottle
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point200-220 °CNot Available
water solubility5.64E+005 mg/LNot Available
logP-2.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.238 mg/mLALOGPS
logP-1.3ALOGPS
logP-8.1ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)11.6ChemAxon
pKa (Strongest Basic)10.23ChemAxon
Physiological Charge5ChemAxon
Hydrogen Acceptor Count18ChemAxon
Hydrogen Donor Count18ChemAxon
Polar Surface Area490.66 Å2ChemAxon
Rotatable Bond Count28ChemAxon
Refractivity297.67 m3·mol-1ChemAxon
Polarizability125.93 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceNot Available
General ReferenceNot Available
External Links
ATC CodesA07AA10J01XB01
AHFS Codes
  • 08:12.28.28
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (72.2 KB)
Interactions
Drug InteractionsNot Available
Food InteractionsNot Available

Targets

1. Bacterial outer membrane

Kind: group

Organism:

Pharmacological action: yes

Actions: incorporation into and destabilization

Components

Name UniProt ID Details

References:

  1. Vaara M: Polymyxins and their novel derivatives. Curr Opin Microbiol. 2010 Oct;13(5):574-81. Epub 2010 Sep 24. Pubmed
  2. Soon RL, Nation RL, Cockram S, Moffatt JH, Harper M, Adler B, Boyce JD, Larson I, Li J: Different surface charge of colistin-susceptible and -resistant Acinetobacter baumannii cells measured with zeta potential as a function of growth phase and colistin treatment. J Antimicrob Chemother. 2011 Jan;66(1):126-33. Epub 2010 Nov 16. Pubmed
  3. Evans ME, Feola DJ, Rapp RP: Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother. 1999 Sep;33(9):960-7. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:12